News wire

U.S. Food and Drug Administration

Stories that name U.S. Food and Drug Administration.

Source check 6 min ago · Newest item 7 hr ago · 1,441 stories this week · 87 of 90 publishers answering · Browse publishers · RSS feed

PI DATA HUBLegal intelligence
Filter stories

U.S. Food and Drug Administration

Friday, November 20

Thursday, November 19

Tuesday, November 17

Monday, November 16

Announcement Illinois Lawyer Now (ISBA)IL

Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois

On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading

Read at Illinois Lawyer Now (ISBA)

Friday, November 13

Announcement Illinois Lawyer Now (ISBA)IL

Illinois Medicaid Filled Nearly 1 Million Prescriptions for Leading GLP-1 Drugs Before the FDA’s Vision Loss Warning

Illinois Medicaid paid for 993,119 prescriptions for nine leading GLP-1 drugs between 2022 and 2025, at a gross cost of $1.1 billion. Every one was filled before November 9, 2026, when the FDA ordered manufacturers to add a warning about a rare form of permanent vision loss called NAION. Ankin Law analyzed four years of... Continue Reading

Read at Illinois Lawyer Now (ISBA)

Thursday, November 12

Recall U.S. Food and Drug Administration (Recalls)

Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen

FOR IMMEDIATE RELEASE – November 12, 2026 - Tampa, Florida. Game Changer Products LLC is voluntarily recalling all lots of 10 Day Forecast capsules to the consumer level. FDA analysis has found the product to be tainted with sildenafil and acetaminophen. Sildenafil is an active ingredient in an FDA

Read at U.S. Food and Drug Administration (Recalls)

Announcement Illinois Lawyer Now (ISBA)IL

FDA Warns Ozempic, Wegovy, and Other GLP-1 Drugs May Cause Permanent Vision Loss

The FDA warns Ozempic, Wegovy, and other GLP-1 drugs may cause permanent vision loss. It is requiring new safety warnings on the popular weight loss and diabetes medications after finding evidence of an increased risk of a serious eye condition that can cause blindness. The November 9, 2026, announcement affects medications including Ozempic, Wegovy, Mounjaro,... Continue Reading

Read at Illinois Lawyer Now (ISBA)

Wednesday, November 11

Tuesday, November 10

Monday, November 9

Safety notice U.S. Food and Drug Administration (MedWatch)

MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication

Read at U.S. Food and Drug Administration (MedWatch)

Friday, November 6

Federal Register notice Federal Register: FDA

Medical Devices; Ear, Nose, and Throat Devices; Classification of the External Mechanical Stimulator for the Relief of Congestion

The Food and Drug Administration (FDA) is classifying the external mechanical stimulator for the relief of congestion into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the external mechanical stimulator for the relief of congestion. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to…

Read at Federal Register: FDA

Thursday, November 5

Federal Register notice Federal Register: FDA

Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm

The Food and Drug Administration (FDA) is classifying the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the digital cervical cytology slide imaging system with artificial intelligence algorithm. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We…

Read at Federal Register: FDA

Connect the news to your market.

Research the firms, offices and conference relationships behind the headlines.

Request research access